Influenza infection results in substantial morbidity and mortality in hospitalized patients, including those who are immunocompromised or pregnant. Antiviral therapy likely provides considerable benefit to these patients, but few studies have been successfully conducted in these high-risk populations, and no drugs are specifically licensed for treating these subgroups. One of the key challenges facing novel antiviral drug development for influenza is determining the appropriate efficacy end points that would enable rapid regulatory approval for drug use in seriously ill patients, for whom risk-benefit assessments differ from those with uncomplicated illness. All available antiviral drugs currently affect viral replication, and respiratory tract viral titers correlate with both symptoms and measures of host inflammatory responses, including cytokine and chemokine expression that are likely responsible for many of the clinical symptoms. Consequently, we outline the evidence to support the use of primary virological end points in studies of antiviral agents involving patients who are hospitalized with severe influenza or those who are at high risk of severe and life-threatening disease.
The principal antiviral drugs used for treating influenza infection are the M2 ion channel blockers and neuraminidase inhibitors. However, the world is now experiencing a pandemic due to a swine origin influenza A(H1N1) virus that is currently only susceptible to neuraminidase inhibitors, and oseltamivir-resistant virus isolates have already been documented [1] [2] [3] . In addition, M2 inhibitor-resistant influenza A(H3N2) viruses and oseltamivir-resistant seasonal H1N1 viruses have been recognized to circulate recently [4] [5] [6] . To our knowledge, no new influenza antiviral therapy has been approved since 1999 in the United States, and none have an indication for treatment of severe disease. In short, there is an urgent need to expeditiously move forward with efficacy trials for influenza therapeutics, particularly for vulnerable patient populations at risk of severe disease. However, despite evidence that early clearance of influenza virus provides a more favorable clinical outcome in ambulatory patients and hospitalized adults [7] , there are a number of challenges to the clinical development and rapid approval of new therapeutic agents to treat high-risk patients and those with severe illness (Table 1).
In a recent draft guidance, the US Food and Drug Administration (FDA) states its reservations with respect to allowing the use of surrogate end points for the accelerated approval of influenza antivirals [8] . As a consequence, sponsors and investigators are confronted with the quandary of identifying suitable end points for clinical studies of novel agents or new indications in these heterogeneous patient groups. In hospitalized patients, comorbidities and other host factors may predominate in determining ultimate out-comes, and clinical outcome measures are not validated. In this commentary, we discuss the need for flexibility in the selection of appropriate end points, and we propose that studies using primary virologic end points are appropriate in these relatively small but high-medical-need groups to better define the optimal management of influenza. Although some issues raised in this commentary will require additional resolution, we suggest alternative approaches for the rapid evaluation of urgently needed new agents and antiviral combinations.
HURDLES TO ANTIVIRAL EFFICACY STUDIES IN HIGH-RISK POPULATIONS
Specific patient groups, including those with comorbidities, pregnant women, young children, and individuals with compromised immunity, are at higher risk for serious influenza-related disease and hospitalization than the general population. However, underlying host conditions, illness manifestations, and clinical outcomes vary widely across such risk groups, and various logistical and scientific challenges exist to conducting antiviral efficacy trials in them (Table 1) . Delayed presentation for care and initiation of antiviral therapy has been shown to be a major variable that influences outcomes in patients with H5N1 illness and appears to be important for those hospitalized with seasonal influenza or with pandemic H1N1 illness [7, [9] [10] [11] [12] [13] [14] [15] .
Of note, most influenza-related hospitalizations in adults with seasonal influenza are related to exacerbations of underlying diseases, and radiologically confirmed pneumonia occurs in р25% of patients [16, 17] . In immunocompromised patients, the risks for influenza and its complications vary widely. For example, influenza in allogeneic stem cell transplant recipients is associated with greater risk of morbidity and mortality than that found in recipients of autologous stem cells [18] , and lung transplant recipients are at higher risk than other solid organ transplant recipients [19] . Although the risks of protracted viral replication, complications, and mortality are higher, initial symptoms may be milder in immunocompromised patients. For example, one study of hematopoietic stem cell transplantation (HSCT) recipients found that most patients presented with runny nose (∼70%), but few presented with fever (∼30%) or cough (∼40%) and none had myalgias [20] .
GOALS OF ANTIVIRAL THERAPY
The overall goals of antiviral therapy in hospitalized patients include (1) improving individual patient outcomes (eg, decreases in mortality, disease progression and development of new complications, length of hospital stay, and time to recovery to premorbid status) ( Table 2) , (2) avoiding serious drug adverse effects, and (3) possibly reducing viral transmission to contacts. The last epidemiologic benefit may be especially important in nosocomial settings or with particularly virulent influenza viruses. The relevant clinical end points depend heavily on the particular patient populations studied, local standards of care, and physician judgment. Many are not applicable to all or even most patients, so that enrollment of sufficient numbers of subjects in prospective clinical trials based on end points such as mortality is impractical in most influenzaaffected populations. For example, only ∼15%-20% of adults hospitalized in developed country settings are admitted to intensive care units (ICUs), and the overall mortality rates in recent studies of adults hospitalized with seasonal influenza have ranged from 1.4% to 8.3% across centers [7, 9, 16, 17, 21, 22] . Studies that focus only on ICU admission or mortality as a primary outcome are likely to require prolonged time frames for accrual of sufficient numbers of patients and also need to consider the many confounding variables that affect clinical outcomes in this heterogeneous patient group.
The times to resolution of objective biomarkers such as fever and abnormal vital signs are short in influenza, even in hospitalized adults, and often confounded by intercurrent use of antipyretic and other symptom-modifying drugs. For example, in the pivotal North American study of oral oseltamivir in otherwise healthy outpatient adults with uncomplicated influenza, the median times to resolution of feverishness were brief (23 h for placebo vs 10 h for oseltamivir). In comparison, the times to alleviation of symptoms (103 h vs 71.5 h) and resumption of usual activities (∼9 vs 6 days) were substantially more prolonged and showed more pronounced differences between treated and untreated individuals [23] . Similarly, in a recent study of intravenous peramivir in hospitalized adults, the median times to clinical stability, based on objective vital signs, were much shorter (17.2-23.7 h) than were the times to resumption of usual activities (13.2 days for oseltamivir vs 8.2-9.2 days for peramivir groups) [24] . Because immunocompromised patients have fewer and milder symptoms than ambulatory immunocompetent patients [20] , and others such as severely ill patients and young children may not be able to accurately describe their symptoms, subjective clinical outcomes are unreliable. In summary, other than mortality, validated clinical end points for hospitalized high-risk patients are not available, and identification of such end points is complicated by the heterogeneity of patient groups.
RATIONALE FOR VIROLOGIC END POINTS IN EVALUATION OF INFLUENZA ANTIVIRAL AGENTS
The primary objective of antiviral therapy is to suppress replication of influenza viruses as rapidly, effectively and completely as possible. Virologic end points reflect the basic mechanism of action of approved and investigational antiviral agents (ie, to inhibit viral replication in affected tissues). Hence, measures of virus replication can hardly be labeled as "surrogate markers," and their use as primary end points to 7 Studies document р20% of adults admitted to medical wards with acute cardiopulmonary conditions or to intensive care units with acute respiratory failure during the influenza season will be the result of influenza infection [52] 7 The CDC definition of ILI lacks sensitivity and specificity in hospitalized adults [26] 7 RAT lacks sensitivity, and sometimes specificity 7 Influenza not commonly screened for in patients admitted to the hospital Recruitment hurdles 7 Small numbers 7 Geographic and seasonal variation in disease 7 Obtaining consent from patients with cognitive impairment (from illness or treatment, eg, hypoxemia, intubation)
Disease pathogenesis, clinical course, and prognosis are affected by:
7 Age of the patient (eg, infants, chronic care facility residents) Heterogeneity of testing among and within immunocompromised categories (ie, frequent testing among lung transplant recipients vs other SOT patients) Poor recognition of influenza because of altered symptom severity and frequency [20] Optimal duration of therapy highly variable which makes design of stop point and interpretation of results with variable lengths of therapy challenging [31] ; based on:
7 Type and severity of immune defect Most patients, subjects, and their guardians are unwilling to participate in placebo-controlled studies for ethical reasons Pediatric populations Severity of influenza illness varies by age [51, [54] [55] [56] Rate of hospitalization is highest among infants younger than 6 months so recruitment of older children may be more difficult; short median duration of hospitalization and nonspecific nature of symptoms Higher levels of virus and greater frequency of direct viral complications may make it easier to establish the correlation of antiviral effect and clinical benefit.
Pharmacokinetics of antiviral drugs in children can be complex and varies by age [57] Studies investigating the pharmacodynamics of antiviral drugs in children thus require understanding the drug pharmacokinetics Antiviral resistance Study designs that attempt to compare a new treatment to standard of care are increasingly confounded by antiviral drug resistance in circulating strains (ie, oseltamivir resistance in seasonal H1N1, M2 inhibitor resistance in H3N2 and the pandemic 2009 influenza A(H1N1) Limited ability to detect and report on susceptibility data for an individual patient's infecting strain 7 Few available techniques 7 Currently, no resistance testing can be done in close proximity to the patient 7 Turn-around time for most assays is on the order of days Small numbers develop resistance during treatment Emergence of antiviral resistance may develop during treatment, particularly with immunocompromised patients and those infected with H5N1 viruses [45, [58] [59] [60] [61] [62] [63] [64] [65] Optimizing antiviral treatment to address drug resistance, in addition to consideration of combination therapy, may mitigate some of this risk evaluate and compare drug efficacy of antivirals for influenza is logical and necessary, especially in heterogeneous populations such as hospitalized and immunocompromised patients. Rapid curtailment of active viral replication is an essential first step to mitigate additional tissue damage and is expected to contribute to more rapid clinical recovery, reduced risk of new complications, amelioration of viral complications, and lower mortality.
Considering the viral etiology of influenza, it should not be surprising that there is a significant correlation between the amount and duration of virus replication and illness manifestations. Animal model studies employing a range of influenza viruses have established that antiviral effects are well correlated with reduced morbidity and mortality [25] . Correlations between measures of viral replication and illness manifestations have also been observed in experimental human infections and in studies of uncomplicated illness in ambulatory patients [27-29, 31-33, 44] .
Studies on experimental human influenza have shown that control of viral replication by neuraminidase inhibitors is associated with both reduced cytokine and chemokine expression and symptom severity [25, 26] . These biomarkers generally correlate with measures of viral replication in the upper respiratory tract (URT) in experimental human influenza [28, 29] , hospitalized adults [7, 30] , and H5N1 patients [14, 27] , but it is currently unclear whether baseline findings and changes in these measures, either in direction or magnitude, predict clinical outcomes.
The virologic course of infection in seriously ill and hospitalized patients has been characterized in a relatively small number of studies to date. As for outpatients, the available data for seriously ill hospitalized patients indicate that viral titers are highest at time of hospitalization and decline subsequently [7, 16, 21, 30] . However, adults hospitalized with seasonal influenza have more protracted viral replication than outpatients with uncomplicated illness, and this prolonged shedding is related to clinical outcomes [7, 16, 21] . One recent study [7] found that nasopharyngeal viral RNA loads showed nonlinear declines with time and that receipt of oseltamivir on or before symptom day 4 was independently associated with accelerated viral clearance and RNA-negativity at 1 week. Furthermore, viral RNA negativity at symptom day 5 or day 7 was associated with shorter hospital stay. An earlier study found that prolonged nasopharyngeal viral RNA detection during admission (14 days) was associated with prolonged hospitalization and that receipt of oseltamivir treatment within 2 days of symptom onset was associated with an estimated 2-day reduction in median length of hospital stay (4 vs 6 days) [16] . Additional analysis found that oseltamivir therapy within 96 h of illness onset was associated with reduced mortality in patients (5 [2.2%] of 232 patients) compared with those who did not receive antiviral treatment (7 [5.6%] of 124 patients; odds ratio, 0.26; 95% confidence interval, 0.08-0.87) [34] . Other retrospective studies from Canada and Thailand also found that oseltamivir therapy, even when delayed beyond 48 h after symptom onset, is associated with reduced mortality in those hospitalized with seasonal influenza [9, 35] . Conversely, delayed time to antiviral treatment has been associated with worse prognosis in those hospitalized with pandemic H1N1 illness [11, 15] .
In hospitalized H5N1-infected patients in Vietnam and Indonesia, levels of viral RNA in throat swabs obtained at admission were higher among patients who died of the infection than in those who survived [27; M de Jong, written communication, 12 October 2009]. Furthermore, in 8 Vietnamese patients followed up during treatment with oseltamivir, viral clearance was associated with clinical benefit: the 4 surviving patients showed rapid declines of viral RNA load in throat swab samples to levels below the threshold of detection within a few days of treatment, whereas the 4 patients who died still had detectable levels of viral RNA after completion of a 5-day treatment course. Additionally, oseltamivir-resistant virus could be isolated from 2 of the patients who did not survive [40] .
Immunosuppressed hosts with influenza usually experience prolonged replication and associated illness, with higher risks of complications and death [18, 36] . One study of bone marrow transplant recipients reported that the mean duration of viral shedding was longer in allogeneic recipients than in autologous recipients (11.1 vs 6.7 days) and in those given higher doses of corticosteroids (14.9 vs 8.9 days) but was shorter in those treated with oseltamivir (7.5 days vs 11.3 days) [37] . The median viral load measured by reversetranscription polymerase chain reaction (RT-PCR) at diagnosis in 1 study of ambulatory HSCT recipients was 5.9 log 10 RNA equivalents/mL (interquartile range, 4.8-6.8 log 10 /mL), and virus was detectable by RT-PCR for 7-28 days (median, 11 days) among patients treated with oseltamivir. Several studies have reported reduced mortality in influenza-infected, highly immunocompromised hosts treated with oseltamivir [19, 37, 38] . However, the occurrence of prolonged high viral replication in immunompromised patients carries a risk of antiviral resistance development, often with adverse outcomes [2, 45, 58, 60] . Likewise, high replication rates during primary seasonal influenza virus infection in children and during human H5N1 infections have been associated with resistance development, the latter being clearly accompanied by therapeutic failure [33, [40] [41] [42] . Optimizing antiviral treatment, including consideration of combination therapy, may mitigate the risks of resistance development and its consequences on antiviral efficacy.
VIROLOGIC CONSIDERATIONS
Standard methods exist for determining viral shedding quantitatively by virus isolation using a number of different cell lines and by viral RNA detection using molecular techniques [7, 22, 23, 30-33, 37, 43-47] . Nevertheless, efforts to standardize collection devices and sampling techniques are essential for clinical studies.
The most commonly reported replication measures have been detection of infectious virus in URT samples to quantitate the duration of viral shedding and measure changes in viral titers over time [23, 30, 32, 33, 37, 46, 47] . Cell-based assays allow detection of infectious virus, which likely correlates with the risk of transmission. Virus isolation also has the advantages of providing virus for additional characterization (eg, drug susceptibility testing, fitness studies). Recent studies have used quantitation of viral RNA (RT-PCR) in patient samples to measure viral loads, because these assays provide greater sensitivity and dynamic range [7, 31, 43, 48, 49] . Viral RNA generally remains detectable in respiratory specimens for longer periods than by viral culture, including in specimens taken from those treated for pandemic H1N1 illness [7, 22, 31, 37, 47] . As discussed above, several recent studies have demonstrated that reductions in quantitative viral RNA levels correlate with improved patient outcomes. However, the clinical importance of detecting low levels of viral RNA in the absence of cultivable virus, especially in those receiving neuraminidase inhibitor therapy, remains to be determined. Consequently, both quantitative cell-based and viral RNA assays should be used in all clinical antiviral trials when possible. As additional data become available, selection of a single optimal assay for each class of antiviral may be defined more clearly.
REGULATORY CONSIDERATIONS FOR USING VIROLOGIC END POINTS IN HIGH-RISK PATIENT POPULATIONS
This position is consistent with federal guidance proposing the use of a surrogate end point "that is reasonably likely, based on epidemiologic, therapeutic, pathophysiologic, or other evidence, to predict clinical benefit or on the basis of an effect on a clinical end point other than survival or irreversible morbidity" (21 CFR 314, subpart H, §314.510). Subpart H of Part 314 to the Code of Federal Regulations describes provisions that allow approval for certain new drug products that have been studied for their safety and effectiveness in treating serious or life-threatening illnesses and that provide meaningful benefit to patients over existing treatments [50] . A marketing approval may be based on adequate and well-controlled clinical trials establishing that the drug product has an effect on an appropriate surrogate end point (see above). Approval under Subpart H also requires sponsors to study the drug further, to verify and describe its clinical benefit, where there is uncertainty as to the relation of the surrogate end point to clinical benefit, or of the observed clinical benefit to ultimate outcome. The FDA may also impose distribution restrictions commensurate with the safety of the product. For example, distribution may be restricted to certain health care practitioners, or, alternatively, distribution can be conditioned on the performance of specified medical procedures.
The potential applicability of Subpart H needs to be taken in context with the needs of patients who have developed serious influenza or those who are at greater risk of serious illness. The morbidity associated with influenza and certain risk factors is well established [18, 36, 39, 51] . Additionally, the body of evidence linking virologic markers to clinical outcomes warrants consideration by sponsors and the FDA with regard to identification and acceptance of clinical trial designs incorporating virologic end points [7] . Sponsors need to consider early the strategies they intend to use to validate proposed virologic end points.
SUGGESTED VIROLOGICAL AND CLINICAL END POINTS FOR STUDIES IN HOSPITALIZED AND IMMUNOCOMPROMISED PATIENTS
For the reasons given above, establishing evidence of virological control of infection makes considerable sense in both managing seriously ill and/or immunocompromised influenza patients (ie, therapeutic monitoring) and studying investigational antiviral regimens in groups at risk for serious influenza-related illness. On the basis of available data in hospitalized adults with seasonal influenza, one could establish criteria for virological success that might be applied in hospitalized populations as evidence of antiviral effectiveness (Table 2) . One such example for individual patients might be a composite of (1) either a sustained early response (eg, time to culture or viral RNA-negativity; greater than 2 log 10 decrease in viral titers by 48 h of therapy) or absence of detectable virus or viral RNA by 5 or 10 days, and (2) no emergence of resistant virus during the course of treatment. Studies evaluating add-on treatments with novel agents or combinations in comparison to monotherapy might be designed to enroll a relatively small number of patients, in which the primary end point would be the rapidity and rate of viral clearance as an indicator of enhanced antiviral effects.
With regard to clinical end points (Table 2), all hospitalized patients have some degree of clinical impairment, so that end points like time to alleviation of illness (ie, the definition used in the pivotal outpatient studies of oseltamivir and zanamivir) and time to return to premorbid functional status or perhaps to prior level of care are more broadly applicable. Risk stratification of patients at enrollment should be considered; correlations between clinical outcomes and risk assessment scores for influenza has recently been reviewed [53] . Return to premorbid status is a composite end point that captures events affecting recovery reflected in this end point (eg, death, delayed discharge, or prolonged disability after the influenza episode) while taking into account the heterogeneity of baseline level of function. Unlike uncomplicated disease in outpatients, it remains to be determined in hospitalized patients whether time to clinical stability or resolution of acute influenza symptoms correlates with eventual functional recovery. Alternatively, one might define clinical failure by death, progression to respiratory failure, continued clinical instability after 36-48 h, or pro-longed hospitalization (eg, у5-7 days in adults). Of course, patients might experience delayed recovery or apparent clinical failure despite effective antiviral therapy because of delayed administration, underlying disease, nonviral complications, or differences in care from center to center.
Data regarding multiple other end points of interest (Table 2) should be routinely collected, while recognizing that their applicability to demonstrating effective antiviral therapy has not been established yet (Table 2 ). One confounding issue with regard to some clinical end points is the standardization of concomitant treatments (eg, antipyretics, immunosuppressive agents, antiinflammatory drugs) that might affect disease pathogenesis and symptom reporting. For clinical end points that might be affected by concomitant drugs, the end point should be considered reached only when all symptom-modifying drugs are stopped.
FUTURE DIRECTIONS
There is an unmet need for potent, welltolerated anti-influenza regimens in hospitalized patients, immunocompromised patients, and those patients at high risk of severe or life-threatening influenza. Although a number of potential challenges exist to the successful implementation of studies of antiviral agents in all populations at increased risk of severe complications (summarized in Table 1 ), selection of an appropriate study end point is critical for approval of new and existing agents in these high-risk populations. Available data suggest that virological end points should be considered as the primary outcome measure in licensure studies of anti-influenza agents for these selected populations. Large prospective studies of virological and clinical outcomes are needed to characterize more fully the link between these 2 outcomes in populations at risk for severe influenza and its complications. Likewise, studies are needed to establish standard methods for collecting data, and virological testing of clinical samples are needed to allow consistent, high-quality data to be derived from studies irrespective of where or when the studies are conducted.
Additionally, there are a number of specific issues that will need to be studied prospectively to optimally design studies with virological end points. Technical factors related to sample collection, processing, transport, and assay methods need to be standardized (see the Appendix, which appears only in the electronic edition of the Journal). In this regard it is currently uncertain how accurately viral replication kinetics in the URT reflect those in the lower respiratory tract. Consequently, studies of hospitalized patients should incorporate sampling from the lower airways (eg, endotracheal aspirates or sputum samples) when feasible. Similarly, collection of nasal and/or oropharyngeal specimens may give different yields, and optimal sampling sites will need to be determined. Study designs should use sampling at both sites because these data may inform future guidance. Prospective studies can also inform the frequency of testing (ie, twice daily, daily, or every other day) and the optimal duration of testing. Technical factors need to considered, including the impact of different shipping conditions (ambient vs frozen) and duration of shipping (ie, 6 h shipping time vs 24-36 h shipping times) on culture and RNA detection of influenza. Lastly, although there are existing studies of expected virological courses in treated and untreated hospitalized adult and stem cell transplant populations, such data are needed from hospitalized solid organ transplant recipients, human immunodeficiency virusinfected patients, pediatric patients, and pregnant women.
Finally, the identification and development of domestic and international hospital-based networks to study influenza and other serious acute respiratory viral illnesses, both during interpandemic periods and when a pandemic or novel pathogen emerges, are urgently needed. These networks could collect critical epidemiological and pathogenesis data, as well as provide an expert group to facilitate antiviral drug studies and advise on clinical management strategies.
